Navigation Links
Aware, Inc. Reports Fourth Quarter and 2007 Financial Results
Date:2/12/2008

company had non-GAAP net income, excluding the effect of stock-based compensation, of $1.3 million, or $0.05 per share.

Michael Tzannes, Aware's chief executive officer, said, "Our 2007 results reflect healthy revenue growth in our DSL test and diagnostics hardware and software product lines as well as biometrics software applications. Looking forward to 2008, we are expecting a rebound in our DSL licensing business. Each of these three product lines, DSL test and diagnostics hardware and software, biometrics and medical imaging software and DSL licensing are well positioned for positive revenue and earnings growth."

Note: Aware's conference call will be broadcast live over the Internet today, February 12, 2008 at 5:00 p.m. Eastern Time. To listen to the call, please go to http://www.aware.com/ir. The conference call may also be heard by calling 617-213-4864 and referencing the confirmation number 36075315. A replay of the call will be archived on our website after the call.

About Aware

Aware is a leading technology supplier for the telecommunications industries. For more than ten years, Aware has pioneered innovations at telecommunications standards-setting organizations and continues to develop and market DSL silicon intellectual property and test and diagnostics products. Its StratiPHY(tm) IP product line supports DSL standards, including ADSL2+ and VDSL2, and has been broadly licensed to leading semiconductor companies. Telecom equipment vendors and phone companies use Aware's DSL test and diagnostics modules and Dr. DSL(R) software to help provision DSL circuits globally. Aware is also a veteran of the biometrics industry, providing biometric and imaging software components used in government systems worldwide since 1992. Aware's interoperable, standard-compliant, field-proven imaging products are used in a number of applications, from border management to criminal justice to medic
'/>"/>

SOURCE Aware, Inc.
Copyright©2008 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6

Related biology news :

1. Aware, Inc. Announces Richard Moberg to Return as CFO
2. Aware, Inc. Introduces Biometrics Software for Tenprint Autocapture
3. MIT reports new twist in microRNA biology
4. Drug aimed at 2 bioterror agents blocks live viral infection, Weill Cornell team reports
5. UVA reports surprising findings related to myotonic muscular dystrophy
6. Rong Li Lab reports protein interactions of MAP kinase signaling pathway
7. WHRC releases 4 key reports
8. BIO-key Reports Third Quarter 2007 Results
9. Emory paleontologist reports discovery of carnivorous dinosaur tracks in Australia
10. Communication Intelligence Corporation Reports Second Quarter 2007 Financial Results
11. BIO-key Reports Second Quarter 2007 Results
Post Your Comments:
*Name:
*Comment:
*Email:
Breaking Biology Technology:Lotus Pharmaceuticals, Inc. Appoints OTC Division Head 2Lotus Pharmaceuticals, Inc. Appoints OTC Division Head 3YM BIOSCIENCES AND THE NATIONAL RESEARCH COUNCIL OF CANADA BIOTECHNOLOGY RESEARCH INSTITUTE (NRC-BRI) PRODUCE NEW BREAST CANCER DRUG CANDIDATES 2YM BIOSCIENCES AND THE NATIONAL RESEARCH COUNCIL OF CANADA BIOTECHNOLOGY RESEARCH INSTITUTE (NRC-BRI) PRODUCE NEW BREAST CANCER DRUG CANDIDATES 3YM BIOSCIENCES AND THE NATIONAL RESEARCH COUNCIL OF CANADA BIOTECHNOLOGY RESEARCH INSTITUTE (NRC-BRI) PRODUCE NEW BREAST CANCER DRUG CANDIDATES 4YM BIOSCIENCES AND THE NATIONAL RESEARCH COUNCIL OF CANADA BIOTECHNOLOGY RESEARCH INSTITUTE (NRC-BRI) PRODUCE NEW BREAST CANCER DRUG CANDIDATES 5Life Line Screening Joins the Vascular Disease Foundation as Corporate Partner 2Life Line Screening Joins the Vascular Disease Foundation as Corporate Partner 3Neurocrine Announces Top-Line Results From 703 Study (Tulip PETAL Study) of Elagolix for Treatment of Endometriosis Pain 2Neurocrine Announces Top-Line Results From 703 Study (Tulip PETAL Study) of Elagolix for Treatment of Endometriosis Pain 3Neurocrine Announces Top-Line Results From 703 Study (Tulip PETAL Study) of Elagolix for Treatment of Endometriosis Pain 4Neurocrine Announces Top-Line Results From 703 Study (Tulip PETAL Study) of Elagolix for Treatment of Endometriosis Pain 5Neurocrine Announces Top-Line Results From 703 Study (Tulip PETAL Study) of Elagolix for Treatment of Endometriosis Pain 6